Search clinical trials for: 90Y-ibritumomab

Total 850 results

University of Wisconsin, Madison
Genentech, Inc.

Terminated

Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance

Non-Hodgkin's Lymphoma

United States
Masonic Cancer Center, University of Minnesota

Terminated

AHN-12 Biodistribution in Advanced Leukemia

Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
University of Southern California
National Cancer Institute (NCI)

Withdrawn

Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

Hepatocellular Carcinoma

United States
CABYC
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Completed

Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02) (LCM-04-02)

Mantle Cell Lymphoma

Spain
French Innovative Leukemia Organisation

Terminated

Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma

B-cell Lymphoma

France
Maisonneuve-Rosemont Hospital
Bayer

Unknown

Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

Non-Hodgkins Lymphoma

Canada
University Hospital of Ferrara

Recruiting

Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2) (FENET-2016)

Neuroendocrine Tumors | Peptide Receptor Radionuclide Therapy (PRRT)

Italy
Ochsner Health System
Boston Scientific Corporation

Recruiting

90Y Transarterial Radioembolization Versus Microwave Ablation in Small Hepatocellular Carcinoma With Hypoalbuminemia (REALM)

Carcinoma, Hepatocellular

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Boehringer Ingelheim

Completed

Ambroxol Lozenges 20mg in Relieving the Pain of Sore Throat in Adolescent Patients With Acute Viral Pharyngitis

Pharyngitis

South Africa
University of Bologna

Completed

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy (FM+R-Z)

Follicular Lymphoma

Italy
Gilead Sciences

Withdrawn

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Diffuse Large B-cell Lymphoma | NHL | Non Hodgkin's Lymphoma | Aggressive NHL

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

Lymphoma

United States
Dayton Children's Hospital
National Institutes of Health (NIH)

Terminated

The Use of VSL#3 in Irritable Bowel Syndrome in Children (VSL#3)

Irritable Bowel Syndrome

United States
Spectrum Pharmaceuticals, Inc

Terminated

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

Diffuse Large B-cell Lymphoma | Follicle Center Lymphoma

United States, France, United Kingdom, Ireland, Israel, Belgium, Spain, Netherlands, Australia, Puerto Rico, Canada, Italy, Austria
Grupo Oncológico para el Tratamiento y el Estudio...

Unknown

Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma (GOTEL-FL1LC)

Follicular Lymphoma

Spain
University of Warmia and Mazury
Stowarzyszenie Pacjentów i Osób Wspierających Chorych na Guzy Neuroendokrynne

Unknown

Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression (POLNETS_PRRT)

Neuroendocrine Tumors

Poland
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Burkitt Lymphoma | Refractory Burkitt Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma | Recurrent Adult Lymphoblastic... and other conditions

United States
Boehringer Ingelheim

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers

Healthy
Dartmouth-Hitchcock Medical Center
Spectrum Pharmaceuticals, Inc; Cephalon

Completed

Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe)

Lymphoma, Follicular

United States
University of Arizona
National Cancer Institute (NCI)

Completed

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL (ESHAP)

Lymphoma

United States
David Bushnell
National Cancer Institute (NCI); National Institutes of Health (NIH); Holden...

Active, not recruiting

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting | Neuroendocrine Tumor, Malignant

United States
The Christie NHS Foundation Trust

Recruiting

Introduction of Y90-PET-CT Post Radioembolisation Therapy Scans (Y90-PET-CT)

Cancer

United Kingdom
PETHEMA Foundation
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea; GELCAB

Completed

ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

Lymphoma

Spain
Centre Hospitalier Universitaire de Nice

Active, not recruiting

Prostatic Arterial Embolization With SQUID (Ethylene Vinyl Alcohol Copolymer ) (SQUID)

Prostatic Hyperplasia, Benign

France
GlaxoSmithKline

Withdrawn

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Large-Cell, Follicular

United States
SCRI Development Innovations, LLC
Sirtex Medical

Completed

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

Colorectal Neoplasms

United States
Nexpep Pty Ltd

Completed

Safety Study of Nexvax2 in Subjects With Coeliac Disease

Celiac Disease | Coeliac Disease

Australia
Nantes University Hospital

Withdrawn

Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL (RITEPRALL)

CD22+ Relapsed/Refractory B-ALL

France
SCRI Development Innovations, LLC
Biogen

Completed

Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma
Centre Leon Berard
OncoTherapy Science, Inc.

Terminated

First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (SYNFRIZZ)

Sarcoma, Synovial

France
The Third Affiliated Hospital of Guangzhou Medical...

Recruiting

The Efficacy of Vosevi in Treating DAA-experienced Patients

Chronic Hepatitis C | Medication Reaction

China
Grupo Español de Linfomas y Transplante Autólogo...

Completed

Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL) (Z-RIC-Allo)

Non-Hodgkin Lymphoma

Spain
Biogen

Terminated

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Novartis Pharmaceuticals

Completed

EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

Netherlands, Canada, United States, Slovakia, United Kingdom
Biogen

Terminated

Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

Colorectal Cancer | Metastases

United States
Takeda

Completed

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

Japanese Healthy Adult Male Participants

Japan
M.D. Anderson Cancer Center
Biogen

Completed

Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma

Lymphoma | Non-Hodgkin's Lymphoma

United States
Masonic Cancer Center, University of Minnesota

Terminated

Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia

Leukemia

United States
Sunnybrook Health Sciences Centre

Completed

Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma (ZEVISS)

Follicular Lymphoma

Canada
BeBetter Med Inc

Active, not recruiting

Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects

Relapsed or Refractory Diffuse Large B-cell Lymphoma

China
Gilead Sciences

Completed

Safety and Efficacy Study of 90Y-hPAM4 at Different Doses

Pancreatic Cancer

United States
AbbVie

Terminated

A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants

Healthy Volunteers

United States
Haag-Streit AG
Aravind Eye Hospitals, India

Not yet recruiting

Clinical Study - ES 900 - 2020-1

Cataract

India
Novartis Pharmaceuticals

Completed

EPO906 Therapy in Patients With Advanced Colorectal Cancer

Colorectal Neoplasms | Colonic Neoplasms

United States
Molecular Insight Pharmaceuticals, Inc.

Withdrawn

Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors

Malignant Carcinoid Tumor
Grupo Español de Linfomas y Transplante Autólogo...

Completed

Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom (Z-BEAM LDGGB)

Non-Hodgkin's Lymphoma

Spain
Beth Israel Deaconess Medical Center

Completed

Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
Istituto Scientifico Romagnolo per lo Studio e...

Terminated

Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas (itTRIOlym)

Recurrent Disease | DLBCL | MCL

Italy

3

Subscribe